Ird Luxturna denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Ird Luxturna
## Why Cigna Denies Luxturna for Inherited Retinal Dystrophy as "Duplicate Therapy"
A duplicate-therapy denial for Luxturna (voretigene neparvovec) in inherited retinal dystrophy (IRD) caused by biallelic RPE65 mutations is an unusual denial category for this drug — because Luxturna is a one-time gene therapy with no close therapeutic equivalent. Cigna's system may have triggered this denial in error (for example, if a prior authorization for a different ocular treatment is on file), or Cigna may be applying an overly broad "duplicate" definition to a situation where it does not apply.
This denial is directly challengeable. The key argument is that Luxturna's mechanism of action — delivering a functional copy of the RPE65 gene directly to retinal cells — is categorically different from any other treatment, and no other approved therapy addresses the same root cause.
## Your Federal Appeal Rights
- ERISA §503: Full-and-fair internal review is available. For a factually incorrect denial category ("duplicate" when there is no true duplicate), internal appeal is often resolved quickly when the factual error is pointed out.
- ACA §2719 external review: Available after internal appeal exhaustion. The external-review window is generally four months from the denial notice. Given the progressive nature of RPE65-associated retinal dystrophy, consider requesting expedited external review — vision loss in this condition is generally irreversible, which qualifies as a serious health risk.
- State insurance department: A "duplicate" denial for a drug with no true therapeutic duplicate may constitute an improper denial ground — worth reporting.
## Concrete Appeal Steps
1. Identify what Cigna considers the "duplicate" — request this in writing. The denial letter should specify it. 2. Obtain Cigna's coverage policy for Luxturna and for the therapy they are calling a duplicate. 3. Have your treating ophthalmologist or retinal specialist draft a letter explaining that the treatments are not therapeutically equivalent and address different aspects of care (or that no true duplicate exists). 4. Submit a targeted internal appeal addressing the specific duplicate claim. 5. If denied, escalate to external review promptly given the risk of irreversible vision loss.
## Documentation to Gather
- Genetic test results: Molecular confirmation of biallelic RPE65 pathogenic variants — this is fundamental to establishing that Luxturna is the only FDA-approved gene therapy for this specific mutation.
- Ophthalmology records: Retinal imaging (OCR, visual field testing, ERG results), specialist notes characterizing the stage and rate of progression of your retinal dystrophy.
- Current treatment list: A complete record of all ocular and systemic treatments currently in use, with your prescriber's explanation of why none constitutes a therapeutic duplicate of Luxturna.
- FDA prescribing label for Luxturna: Documents the unique mechanism and the specific mutation-based indication — supporting the argument that no true duplicate exists.
- Prescriber letter: Should address the duplicate claim point by point, explaining the mechanistic and clinical distinction between Luxturna and whatever Cigna identified as duplicative.
## Criteria-Mapping Structure
| Cigna's "Duplicate" Claim | Your Rebuttal Evidence | |---|---| | [Therapy Cigna identified as duplicative] | [Mechanism difference; FDA label distinction; specialist explanation] | | [Any additional criteria Cigna raised] | [Exact chart documentation] |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →